Literature DB >> 19111797

The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target.

Steven Christopher Smith1, Dan Theodorescu.   

Abstract

Bladder cancer is a relatively common and strikingly costly malignancy. Here, we will focus on recent advances in our understanding of the molecular pathogenesis of metastatic bladder cancer, a stage of this disease curable in only a minority of patients. Our group has recently investigated the role of a class of small G-proteins known as the Ras-like or Ral GTPases and their role in this disease. These signaling proteins, regulated by the Ras pathway and other mechanisms, have been shown to be necessary for key cellular phenotypes associated with transformation or cancer progression in diverse cancer systems. In bladder cancer we have observed that these GTPases are overexpressed, are necessary for key phenotypes in models of bladder cancer progression, and finally, are essential for the regulation of expression of key molecules, including the prognostic marker and cell surface GPI-linked glycoprotein, CD24. These findings are reviewed here and suggest that Ral GTPases and their downstream pathways constitute key mediators of bladder cancer progression and may include targets for future therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19111797      PMCID: PMC3904428          DOI: 10.1016/j.urolonc.2008.04.012

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  36 in total

1.  Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB.

Authors:  D O Henry; S A Moskalenko; K J Kaur; M Fu; R G Pestell; J H Camonis; M A White
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Functional genomic comparison of lineage-related human bladder cancer cell lines with differing tumorigenic and metastatic potentials by spectral karyotyping, comparative genomic hybridization, and a novel method of positional expression profiling.

Authors:  Michael A Harding; Karen C Arden; James W Gildea; John J Gildea; Elizabeth J Perlman; Carrie Viars; Dan Theodorescu
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

Review 3.  Ral-GTPases: approaching their 15 minutes of fame.

Authors:  Larry A Feig
Journal:  Trends Cell Biol       Date:  2003-08       Impact factor: 20.808

4.  The small-GTPase RalA activates transcription of the urokinase plasminogen activator receptor (uPAR) gene via an AP1-dependent mechanism.

Authors:  E Okan; V Drewett; P E Shaw; P Jones
Journal:  Oncogene       Date:  2001-04-05       Impact factor: 9.867

5.  RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

Authors:  John J Gildea; M Jabed Seraj; Gary Oxford; Michael A Harding; Garret M Hampton; Christopher A Moskaluk; Henry F Frierson; Mark R Conaway; Dan Theodorescu
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer.

Authors:  J J Gildea; W L Golden; M A Harding; D Theodorescu
Journal:  Genes Chromosomes Cancer       Date:  2000-03       Impact factor: 5.006

7.  The role of Ral A in epidermal growth factor receptor-regulated cell motility.

Authors:  John J Gildea; Michael A Harding; M Jabed Seraj; Kay M Gulding; Dan Theodorescu
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

8.  Expression profiling of Ral-depleted bladder cancer cells identifies RREB-1 as a novel transcriptional Ral effector.

Authors:  G Oxford; S C Smith; G Hampton; D Theodorescu
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

Review 9.  The Aurora kinases: role in cell transformation and tumorigenesis.

Authors:  Hiroshi Katayama; William R Brinkley; Subrata Sen
Journal:  Cancer Metastasis Rev       Date:  2003-12       Impact factor: 9.264

Review 10.  The health economics of bladder cancer: a comprehensive review of the published literature.

Authors:  Marc F Botteman; Chris L Pashos; Alberto Redaelli; Benjamin Laskin; Robert Hauser
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

View more
  13 in total

1.  Role of CD24 in anoikis resistance of ovarian cancer cells.

Authors:  Yan-Hui Li; Xiang Sun; Hong-Bo Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

Review 2.  Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.

Authors:  Margaret A Knowles; Carolyn D Hurst
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 3.  The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer.

Authors:  Sunny Guin; Dan Theodorescu
Journal:  Acta Pharmacol Sin       Date:  2015-01-05       Impact factor: 6.150

4.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

5.  Different metastasis promotive potency of small G-proteins RalA and RalB in in vivo hamster tumor model.

Authors:  Vera A Rybko; Anna V Knizhnik; Andrei V Komelkov; Vasily N Aushev; Lyubov S Trukhanova; Elena M Tchevkina
Journal:  Cancer Cell Int       Date:  2011-06-29       Impact factor: 5.722

Review 6.  Ral signaling pathway in health and cancer.

Authors:  Adel Rezaei Moghadam; Elham Patrad; Elham Tafsiri; Warner Peng; Benjamin Fangman; Timothy J Pluard; Anthony Accurso; Michael Salacz; Kushal Shah; Brandon Ricke; Danse Bi; Kyle Kimura; Leland Graves; Marzieh Khajoie Najad; Roya Dolatkhah; Zohreh Sanaat; Mina Yazdi; Naeimeh Tavakolinia; Mohammad Mazani; Mojtaba Amani; Saeid Ghavami; Robyn Gartell; Colleen Reilly; Zaid Naima; Tuba Esfandyari; Faris Farassati
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

7.  PGE2 promotes renal carcinoma cell invasion through activated RalA.

Authors:  Z Li; Y Zhang; W J Kim; Y Daaka
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

8.  A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness.

Authors:  Laura Grau; Jose L Luque-Garcia; Pilar González-Peramato; Dan Theodorescu; Joan Palou; Jesus M Fernandez-Gomez; Marta Sánchez-Carbayo
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

9.  Clinical value of CD24 expression in retinoblastoma.

Authors:  Jia Li; Changqing Li; Hongfeng Yuan; Fang Gong
Journal:  J Biomed Biotechnol       Date:  2012-06-14

10.  Ral-Arf6 crosstalk regulates Ral dependent exocyst trafficking and anchorage independent growth signalling.

Authors:  Archana Pawar; Jeremy A Meier; Anwesha Dasgupta; Neha Diwanji; Neha Deshpande; Kritika Saxena; Natasha Buwa; Siddhi Inchanalkar; Martin Alexander Schwartz; Nagaraj Balasubramanian
Journal:  Cell Signal       Date:  2016-06-04       Impact factor: 4.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.